A new study led by researchers at Mount Sinai Health System has identified distinct biological signatures in patients with ...

Ustekinumab is more efficacious than vedolizumab or anti-TNFs as second- or third-line biologic therapy for perianal Crohn disease.

Researchers at New York City-based Mount Sinai Health System have identified distinct biological markers in patients with mild Crohn’s disease, potentially paving the way for more personalized and ...

In this video, Joseph M. Runde, DO, attending physician in gastroenterology, hepatology and nutrition at Ann & Robert H. Lurie Children’s Hospital of Chicago and assistant professor of pediatrics at ...

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is often perceived as a condition ...